LY
Lyra Therapeutics, Inc.
LYRA · OTC
$0.03 -85.00% (-$0.17)
1M -85.00%
Market Cap $355.0K
P/E Ratio -
Div. Yield -
ROE -
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
100 /100
Cheap P/S 0.89x
P/FCF N/A
P/B N/A
Growth
58 /100
Stable Book val. growth 6.28%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak FCF margin 7,280.15%
Op. margin 7,794.47%
Gross margin 100.00%
Quality
0 /100
Poor ROA 80.09%
Asset turnover 0.01x
ROIC 98.82%
Debt
85 /100
Low Current ratio 1.71x
Debt/Assets N/A
Net debt/EBITDA N/A
Stability
59 /100
Moderate EPS volatility 39.67%
Profitable years 0
Beta 0.71x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LYRA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Carmichael S. Roberts Jr.
Employees
27
Headquarters
Watertown
Upcoming events
17 NOV
Earnings
Upcoming earnings report